{"id":"W4390963940","doi":"10.1007/s00262-023-03593-2","title":"Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Cancer Institute; Sanofi","keywords":"Pembrolizumab; Medicine; Melanoma; Aflibercept; Oncology; Internal medicine; Adverse effect; Immune system; Combination therapy; Immunology; Gastroenterology; Immunotherapy; Cancer research; Bevacizumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001469211,0.0006013297,0.0009323184,0.0006272407,0.0001384967,0.00007404389,0.0002851817,0.0002707544,0.001104195],"category_scores_gemma":[0.000008433239,0.000446843,0.0002482173,0.00105123,0.0002711305,0.0002125077,0.00003710698,0.0003655146,0.00009791193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002934147,"about_ca_system_score_gemma":0.0008983068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009530619,"about_ca_topic_score_gemma":0.0002907978,"domain_scores_codex":[0.9971783,0.0001064874,0.0006720182,0.0008860564,0.0003257437,0.0008314066],"domain_scores_gemma":[0.9986651,0.00008082672,0.0001119566,0.0008997829,0.0001311477,0.0001112136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1560634,0.001031149,0.03210874,0.0001565838,0.004326374,0.0003022072,0.006556165,0.0001189804,0.1725623,0.0001691146,0.00106604,0.6255389],"study_design_scores_gemma":[0.03617662,0.01000919,0.7009888,0.001140769,0.0001308093,0.0000425154,0.0002905898,0.00002342094,0.009181685,0.00002346347,0.2412377,0.0007544625],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9301785,0.06344885,0.00005238822,0.002324719,0.00109524,0.001795161,0.00009740575,0.0002601985,0.0007474994],"genre_scores_gemma":[0.9829974,0.01134422,0.0003602141,0.001418007,0.0001009859,0.0008573698,0.0001050256,0.0001770365,0.002639742],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.66888,"threshold_uncertainty_score":0.9998089,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009877809274415455,"score_gpt":0.2785006858800478,"score_spread":0.2686228766056323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}